{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"groups":[{"description":"Patients receiving peripheral blood stem cell mobilization, chemotherapy (cyclophosphamide + Mesna, growth factor (Granulocyte-colony stimulating factor) and autologous Peripheral Blood Stem Cell transplant with high dose melphalan (200 mg/m\\^2). Post-transplant maintenance therapy is then prescribed if appropriate.","id":"OG000","title":"Chemotherapy and Transplant Treatment"}],"populationDescription":"Data not available for this outcome at our center, maintenance treatment data for participants is not available as the EPIC system was not in place when this study was conducted and participants moved to different clinics so follow-up details were no available.","reportingStatus":"POSTED","timeFrame":"Post transplant phase","title":"Dropout Rate From Maintenance Therapy","type":"SECONDARY"}